Calcium phosphate

Oral
Dietary supplement

Conditions associated with hypercalcaemia and hypercalciuria.

Renal impairment (frequent monitoring of serum calcium and phosphorus is recommended); sarcoidosis; history of nephrolithiasis. Avoid IV admin of calcium in patients on cardiac glycosides. Increased risk of hypercalcaemia and hypercalciuria in hypoparathyroid patients receiving high doses of vitamin D. Caution when used in patients with history of kidney stones. Patients should be advised to administer vitamin D concurrently to optimise calcium absorption. Pregnancy.

Gi discomfort e.g. constipation, nausea, vomiting, bloating and gas. Dry mouth, hypercalcaemia, hypophosphataemia, milk-alkali syndrome.

May reduce the efficacy of calcium-channel blockers. Concurrent admin of IV calcium salt with cardiac glycosides may lead to serious adverse events. Increased risk of hypercalcaemia when used with thiazide diuretics. May reduce absorption of tetracycline, alendronate, atenolol, iron, quinolone antibiotics, sodium fluoride and zinc.

Increased risk of osteoporosis with ethanol.

Description:
Mechanism of Action: Calcium phosphate is used to prevent or treat negative calcium balance. It prevents or reduces the rate of bone loss. The calcium in calcium salts aids in nerve and muscle performance and allows normal cardiac function.
Pharmacokinetics:
Absorption: Absorbed largely from the small intestine by active transport and passive diffusion.
Distribution: Crosses the placenta and is distributed into breast milk.
Excretion: Excess calcium is mainly excreted renally. Unabsorbed calcium is removed in the faeces, along with that secreted in the bile and pancreatic juice.

Electrolytes